5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors

US9440992B2 · kind B2 · utility

Assignee

• Acturum Life Science AB · SE

Inventors

• Gunnar Nordvall · Gately Drive, SE
• Colin Ray · Gately Drive, SE
• Tobias Rein · Gately Drive, SE
• Daniel Sohn · Gately Drive, SE

Key dates

• Filing date: Dec 28, 2010
• Grant date: Sep 13, 2016
• Expiry date: May 19, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.